Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate…
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that…
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)…
Persephone Persephone - A First-Of-Its-Kind Synbiotic Newly released data shows that nine in ten babies lack critical gut microbes needed…
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small…
NEW YORK and PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new…
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET…
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today…
Avidion brings clarity to immune drug-tumor interactions, helping scientists identify better cell therapy candidates, understand mechanisms, and advance with confidence.…
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in…